Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016 - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1212369

Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Description:

Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

“Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global gastroesophageal reflux disease market. The report identifies the key trends shaping and driving the global gastroesophageal reflux disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global gastroesophageal reflux disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.

Scope

The report provides information on the key driver and challenges of the global GERD market. Its scope includes:
- Annualized global GERD market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
- Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include H+/K+ ATPase Inhibitor, H2 antagonist, 5-HT4 receptor agonist, GABA-B receptor Agonist and mGluR5 antagonist.
- Analysis of the current and future market competition in the global GERD market. Key market players covered are AstraZeneca, Addex Pharmaceuticals, XenoPort and Vecta.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with GERD.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global gastro-oesophageal reflux disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastro-oesophageal reflux disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global gastro-oesophageal reflux disease market landscape? - Identify, understand and capitalize.

Contents:

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 GERD Therapeutics Market: Market Characterization
2.1 Overview
2.2 GERD Therapeutics Market Size
2.3 GERD Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the GERD Therapeutics Market
2.4.1 Drivers for the GERD Therapeutics Market
2.4.2 Barriers for the GERD Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 GERD Therapeutics Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Portfolio for Major Marketed Products in the GERD Therapeutics Market
3.3.1 Nexium (esomeprazole)
3.3.2 Aciphex (rabeprazole sodium)
3.3.3 Prevacid (lansoprazole)
3.3.4 Prilosec (omeprazole)
3.3.5 Protonix (pantoprazole sodium)
3.3.6 Tagamet (cimetidine)
3.3.7 Pepcid (famotidine)
3.3.8 Zantac (ranitidine hydrochloride)
3.3.9 Axid (nizatidine)
3.4 Key Takeaway
4 GERD Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework
4.3 GERD Therapeutics - Promising Drugs under Clinical Development
4.4 Molecule Profiles for Promising Drugs under Clinical Development
4.4.1 XP19986
4.4.2 AZD3355
4.4.3 ADX10059
4.4.4 Vecam
4.5 GERD Therapeutics Market - Pipeline Assessment by Mechanism of Action
4.6 GERD Therapeutics Market - Pipeline Assessment by Phase of Clinical Development
4.6.1 GERD Therapeutics - Phase III Clinical Pipeline
4.6.2 GERD Therapeutics - Phase II Clinical Pipeline
4.6.3 GERD Therapeutics - Phase I Clinical Pipeline
4.6.4 GERD Therapeutics - Preclinical Pipeline
4.6.5 Discontinued/Suspended Drugs for GERD
4.7 Key Takeaway
5 GERD Therapeutics Market: Implications for Future Market Competition
6 GERD Therapeutics Market: Key Players in the GERD Therapeutics Market
6.1 XenoPort, Inc.
6.1.1 Company Overview
6.1.2 XP19986
6.2 AstraZeneca
6.2.1 Company Overview
6.2.2 AZD3355
6.3 Addex Pharmaceuticals
6.3.1 Company Overview
6.3.2 ADX10059
6.4 Vecta Ltd. (Vecta)
6.4.1 Company Overview
6.4.2 Vecam
7 GERD Therapeutics Market: Appendix
7.1 Market Definition
7.2 Abbreviations
7.3 Research Methodology
7.4 Coverage
7.5 Secondary Research
7.6 Primary Research
7.7 Models
7.8 Forecasts
7.9 Expert Panels
7.10 Consulting
7.11 Contact Us
7.12 Disclaimer

Summary:

“Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global Gastroesophageal Reflux Disease (GERD) market. The report identifies the key trends shaping and driving the global GERD market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global GERD sector.

The GERD Therapeutics Market is Forecast to Show Decline Until 2016

GlobalData’s analysis suggests that the global GERD market was worth $ 21.5 billion in 2009. It is forecast to decline at a compound annual growth rate (CAGR) of 9% for the next seven years to reach $11.7 billion by 2016. The high projected rate of decline is primarily attributable to the patent expiries of all proton pump inhibitors (PPIs) by the end of the forecast period. Increase in the treatment seeking population, the diagnosis population and long term anti-reflux maintenance therapy are expected to sustain the GERD market.

GERD Therapeutics Market, Global, Revenue Forecasts ($ billion), 2009-2016

GERD Market has Strong Competition Between the Several Marketed Products

Publisher analyzed the current competitive landscape for GERD drugs and found the competition to be strong. There are several marketed products for the symptomatic relief of GERD, which include antacids, H2 receptor antagonists, and PPIs. All treatments are based on attempts to decrease gastric acid production; neutralize gastric acidity; facilitate gastric emptying; restore lower esophageal sphincter function and decrease the frequency of transient lower esophageal sphincter relaxations (TLESRs). Monotherapy regimens and combination therapies have satisfactory efficacy and safety profiles. However, patent expiries of the major prescribed PPIs during the forecast period have raised concerns, meaning that the GERD market will become increasingly genericized. New entrants into the market will be forced to match or exceed the efficacy and safety profiles of the currently marketed products.

Weak Clinical Pipeline with Several Me-too Molecules

GlobalData analyzed the GERD pipeline and found it to be weak. The pipeline for GERD consists of more than 45 molecules currently in development for various disease segments. Approximately 43% of the GERD pipeline consists of me-too molecules. In Phase III alone, there are 10 me-too molecules and seven product extensions including H+/K+ ATPase inhibitors and H2 receptor antagonists. These products are expected to be approved for use in infants and children. Phase II products with novel mechanisms of action seem to be more promising in targeting areas such as relieving nighttime symptoms, achlorhydria (absent acid secretion), providing symptomatic relief to GERD patients inadequately responding to PPIs and importantly, addressing the cause of the disease. A weak clinical pipeline coupled with low unmet needs in the GERD market is expected to negatively impact the market’s growth rate during the forecast period.

Companies Mentioned

XenoPort, Inc. AstraZeneca Addex Pharmaceuticals Vecta Ltd. (Vecta)

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1212369

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.